This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...
You have to be a subscriber to view this page.

Health Care & Hospital Law

Jan. 4, 2011

Drug Delays Deals Are Lucrative and Rising

With few wins to date, the Federal Trade Commission hasn't given up on its mission to end patent settlements between pharmaceutical companies and generic drug manufacturers.


By Mandy Jackson


Daily Journal Staff Writer


Despite little success, the Federal Trade Commission hasn't given up on its mission to end patent settlements between pharmaceutical companies and generic drug manufacturers.


The FTC claims "pay-for-delay" agreements in which patent holders pay competitors to postpone the launch of generic versions of brand-name medications violate antitrust law by limiting competition, costing consumer...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up